Trials / Terminated
TerminatedNCT00083486
Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effectiveness of different doses of epoetin alfa for treating anemia in patients who have cancer; or patients who no longer have any signs of cancer, but remain anemic as a result of their treatment. These patients should not be currently receiving chemotherapy or radiotherapy. A subject's participation in the study will last approximately 6 months. Subjects will receive weekly doses of epoetin alfa or placebo. Their hemoglobin will be tested every week.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | epoetin alfa |
Timeline
- Start date
- 2004-02-01
- Completion
- 2004-10-01
- First posted
- 2004-05-27
- Last updated
- 2011-04-27
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00083486. Inclusion in this directory is not an endorsement.